Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
نویسندگان
چکیده
OBJECTIVE The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the Therapeutics and Technology Assessment Subcommittee in 2003 concluded that mitoxantrone probably reduced clinical attack rates, MRI activity, and disease progression. Subsequent reports of decreased systolic function, heart failure, and leukemia prompted the US Food and Drug Administration to institute a "black box" warning in 2005. This review was undertaken to examine the available literature on the efficacy and safety of mitoxantrone use in patients with MS since the initial report. METHODS Relevant articles were obtained through a review of the medical literature and the strength of the available evidence was graded according to the American Academy of Neurology evidence classification scheme. RESULTS The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy. Systolic dysfunction occurs in approximately 12% of patients with MS treated with mitoxantrone, congestive heart failure occurs in approximately 0.4%, and leukemia occurs in approximately 0.8%. The number needed to harm is 8 for systolic dysfunction and 123 for TRAL. There is no new efficacy evidence that would change the recommendation from the previous report. CONCLUSIONS The risk of systolic dysfunction and leukemia in patients treated with mitoxantrone is higher than suggested at the time of the previous report, although comprehensive postmarketing surveillance data are lacking.
منابع مشابه
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers use of mitoxantrone in the treatment of MS. Mitoxantrone probably reduces the clinical attack rate and reduces attack-related MRI outcomes in patients with relapsing MS (Type B recommendation). Also, mitoxantrone may have a beneficial effec...
متن کاملDoes Mesenchymal Stem Cell Therapy Help Multiple Sclerosis Patients? Report of a Pilot Study
Background: Mesenchymal stem cells (MSCs) with their potential to differentiate into mesodermal and non-mesodermal lineages have several immunomodulatory characteris-tics. These properties make them promising tools in cell and gene therapy. Objective: To evaluate the potential therapeutic applications of autologous MSC in improving clinical manifestations of MS patients. Methods: Ten patients w...
متن کاملReport of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
2010;74;691 Neurology Hans D. Katzberg, Ahmir H. Khan and Yuen T. So of Neurology Technology Assessment Subcommittee of the American Academy evidence-based review) : Report of the Therapeutics and Assessment: Symptomatic treatment for muscle cramps (an January 10, 2013 This information is current as of http://www.neurology.org/content/74/8/691.full.html located on the World Wide Web at: The onl...
متن کاملDisease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
متن کامل
Subcommittee of the American Academy of Neurology Evidence-based Review): Report of the Therapeutics and Technology Assessment Assessment: Botulinum Neurotoxin for the Treatment of Movement Disorders (an Assessment: Botulinum Neurotoxin for the Treatment of Movement Disorders (an Evidence-based Review)
2008;70;1699-1706 Neurology Jankovic, B. Karp, C. L. Ludlow, J. M. Miyasaki, M. Naumann and Y. So D. M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, M. Hallett, J. Subcommittee of the American Academy of Neurology evidence-based review): Report of the Therapeutics and Technology Assessment Assessment: Botulinum neurotoxin for the treatment of movement disorders (an This informatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Neurology
دوره 74 18 شماره
صفحات -
تاریخ انتشار 2010